Effective pharmacotherapy of osteoporosis in perimenopause

Osteoporosis (OP) is a disease characterized by a decrease in bone mineral density (BMD) and a high risk of fractures. In perimenopausal women with a disturbed hormonal background, the risk of developing this pathology increases significantly. Special diagnostic methods and therapy that take into account the etiopathogenesis of the disease can reduce the disability rates associated with OP among patients of this group. The article provides data on the results of examination and treatment of 57 perimenopausal women with OP and reveals the potential of diagnostics that allows evaluating the effectiveness of therapy. The drug "Osteomed Forte" has shown effectiveness in reducing and closing cavities in the trabecular bone sections in patients with verified OP and androgen deficiency, and improving hormonal status in perimenopause allowed to suspend the development of OP and even achieve its partial regression.